[{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"edef415f-bd84-49a1-9a8c-360704fed600","acronym":"","url":"https://clinicaltrials.gov/study/NCT05786924","created_at":"2023-03-28T14:04:59.609Z","updated_at":"2024-07-02T16:35:02.207Z","phase":"Phase 1","brief_title":"A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers","source_id_and_acronym":"NCT05786924","lead_sponsor":"Black Diamond Therapeutics, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S241656"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-21"},{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"}]